A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
At a glance
- Drugs MG 1111 (Primary) ; Varicella zoster virus vaccine live
- Indications Varicella zoster virus infections
- Focus Adverse reactions
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 02 Sep 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.
- 24 Feb 2015 New trial record